<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02318056</url>
  </required_header>
  <id_info>
    <org_study_id>ABR-SIUSOM-14-002</org_study_id>
    <nct_id>NCT02318056</nct_id>
  </id_info>
  <brief_title>The Burn Glove Trial - Hand Burn Dressing Pilot</brief_title>
  <official_title>The Burn Glove Trial-A Randomized Controlled Trial of Dressings for Partial Thickness Hand Burns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Illinois University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern Illinois University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim 1: To determine if one of three burn dressings provides a less painful healing
      experience for partial thickness hand.

      Specific Aim 2: To evaluate if one of three dressings provides greater functionality during
      and after healing of partial thickness hand burns.

      Specific Aim 3: To determine if one of three burn dressings promotes aesthetically superior
      healing results for partial thickness hand burns.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Various products are on the market and available for use on partial thickness burns to the
      hand/s. Our current institutional standard of care is to use Xeroform Gauze (Coviden,
      Mansfield, MA) and Bacitracin Ointment (Fougera, Melville, NY) to promote a moist
      antibacterial healing environment with the ability to monitor the healing progress daily.
      However, silver (AG) based dressings that employ nanocrystalline technology with hydrofiber
      (Aquacel AG burn; ConvaTec, Princeton, NJ) or soft silicone foam (Mepilex AG ; Molnlycke
      Health Care, Dunstable, United Kingdom) have been well accepted as alternative dressing
      solutions. These dressings have longer interval times between changes, leading to a reported
      increase in patient comfort, diminished skin shearing/stripping, and rapid
      re-epithelialization.

      Given the anatomic intricacies, partial thickness burns to the hand present a challenge in
      dressing selection. Recently, ConvaTec unveiled the Aquacel AG Burn Glove for use on partial
      thickness hand burns. In line with this idea, our institution has now begun to fashion a
      novel burn glove out of Mepilex Transfer AG with good success. To date there are no known
      studies that compare Xeroform/Bacitracin, Aquacel AG burn glove or Mepilex Transfer AG
      dressing. The goal of this study is to compare these three burn dressings used to treat
      partial-thickness hand burns and their impact on pain, function, and aesthetic outcomes. We
      will also explore psychosocial issues related to hand burn dressing changes.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to reorganization.
  </why_stopped>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain</measure>
    <time_frame>baseline to 6 months post-burn injury</time_frame>
    <description>pain as measured by the Patient and Provider Scar Assessment Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>baseline to 6 months post-burn injury</time_frame>
    <description>pain as measured by the Michigan Hand Outcomes Questionnaire (MHQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>baseline to 6 months post-burn injury</time_frame>
    <description>pain as measured by the Disabilities of the Arm, Shoulder and Hand Scale, Quick (QuickDASH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functionality</measure>
    <time_frame>baseline to 6 months post-burn injury</time_frame>
    <description>functionality as measured by the Michigan Hand Outcomes Questionnaire (MHQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functionality</measure>
    <time_frame>baseline to 6 months post-burn injury</time_frame>
    <description>functionality as measured by the Disabilities of the Arm, Shoulder and Hand Scale, Quick (QuickDASH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aesthetic appearance</measure>
    <time_frame>baseline to 6 months post-burn injury</time_frame>
    <description>scar formation and aesthetic appearance measured using the Vancouver Scar Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aesthetic appearance</measure>
    <time_frame>baseline to 6 months post-burn injury</time_frame>
    <description>scar formation and aesthetic appearance measured using the the Patient and Provider Scar Assessment Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life</measure>
    <time_frame>baseline to 6 months post-burn injury</time_frame>
    <description>quality of life measured by the psychosocial scales: Burn Specific Health Scale (BSHS)</description>
  </other_outcome>
  <other_outcome>
    <measure>resilience</measure>
    <time_frame>baseline to 6 months post-burn injury</time_frame>
    <description>resilience measured by the Connor-Davidson Resilience Scale (CD-RISC)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Aquacel® Ag Burn Glove</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of Aquacel® Ag Burn Glove burn dressing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mepilex® Transfer Ag</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of Mepilex® Transfer Ag burn dressing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xeroform®/Bacitracin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of Xeroform® burn dressing and Bacitracin® topical antibiotic</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aquacel® Ag Burn Glove</intervention_name>
    <description>burn dressing</description>
    <arm_group_label>Aquacel® Ag Burn Glove</arm_group_label>
    <other_name>ConvaTec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mepilex® Transfer Ag</intervention_name>
    <description>burn dressing</description>
    <arm_group_label>Mepilex® Transfer Ag</arm_group_label>
    <other_name>Safetac®</other_name>
    <other_name>Molnlycke® Health Care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antibiotic</intervention_name>
    <description>antibiotic burn dressing</description>
    <arm_group_label>Xeroform®/Bacitracin®</arm_group_label>
    <other_name>Bacitracin®</other_name>
    <other_name>Xeroform®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting at Memorial Medical or Southern Illinois University (SIU) Health
             Care

          -  Patients with partial-thickness burn injuries to the dorsum and/or palm of the hand/s
             that exceeds ½% total body surface area (TBSA) for at least one hand.

          -  &lt; 10% TBSA 2nd and 3rd degree burn injuries

          -  Initial clinical presentation &lt; 5 days post burn injury

        Exclusion Criteria:

          -  &lt; ½ % TBSA involving the hand

          -  &gt; 10%TBSA burn injuries

          -  &gt; 60 years of age

          -  &lt; 8 years of age

          -  Patients (or parents of minors) without cognitive capacity to comprehend informed
             consent

          -  Presentation &gt; 5 days post-burn injury event

          -  Pregnant women

          -  Full thickness/3rd degree burns to the dorsal and/or palmer hand/s

          -  Exposed vital structures (tendons, nerves, bone, vessels)

          -  Uncontrolled Type II Diabetes

          -  Type I Diabetes

          -  History of Chronic Obstructive Pulmonary Disease

          -  Have a known allergy to silver products

          -  Signs of infection on initial clinical presentation (presence of purulent drainage,
             significant cellulitis, and/or fever)

          -  Smoke/inhalation injuries requiring ventilation

          -  Critically ill patients requiring intensive care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nada N Berry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Illinois University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794-9640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siumed.edu/surgery/plastics/clinical-research.html</url>
    <description>Institute for Plastic Surgery, Office for Clinical Research</description>
  </link>
  <reference>
    <citation>Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD002106. doi: 10.1002/14651858.CD002106.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;3:CD002106.</citation>
    <PMID>18843629</PMID>
  </reference>
  <reference>
    <citation>Robson MC, Smith DJ Jr, VanderZee AJ, Roberts L. Making the burned hand functional. Clin Plast Surg. 1992 Jul;19(3):663-71. Review.</citation>
    <PMID>1633673</PMID>
  </reference>
  <reference>
    <citation>Kamolz LP, Kitzinger HB, Karle B, Frey M. The treatment of hand burns. Burns. 2009 May;35(3):327-37. doi: 10.1016/j.burns.2008.08.004. Epub 2008 Oct 25. Review.</citation>
    <PMID>18952379</PMID>
  </reference>
  <reference>
    <citation>Walburn J, Vedhara K, Hankins M, Rixon L, Weinman J. Psychological stress and wound healing in humans: a systematic review and meta-analysis. J Psychosom Res. 2009 Sep;67(3):253-71. doi: 10.1016/j.jpsychores.2009.04.002. Epub 2009 Jul 2. Review.</citation>
    <PMID>19686881</PMID>
  </reference>
  <reference>
    <citation>Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: review of the literature. Burns. 2007 Mar;33(2):139-48. Epub 2006 Nov 29. Review.</citation>
    <PMID>17137719</PMID>
  </reference>
  <reference>
    <citation>Hollinger MA. Toxicological aspects of topical silver pharmaceuticals. Crit Rev Toxicol. 1996 May;26(3):255-60. Review.</citation>
    <PMID>8726163</PMID>
  </reference>
  <reference>
    <citation>Bowler PG, Jones SA, Walker M, Parsons D. Microbicidal properties of a silver-containing hydrofiber dressing against a variety of burn wound pathogens. J Burn Care Rehabil. 2004 Mar-Apr;25(2):192-6.</citation>
    <PMID>15091147</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2014</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hand</keyword>
  <keyword>burns</keyword>
  <keyword>thermal</keyword>
  <keyword>dressing</keyword>
  <keyword>Aquacel®</keyword>
  <keyword>Mepilex® Transfer Ag</keyword>
  <keyword>Xeroform®</keyword>
  <keyword>Bacitracin®</keyword>
  <keyword>partial thickness</keyword>
  <keyword>epithelialization</keyword>
  <keyword>wound healing</keyword>
  <keyword>scar</keyword>
  <keyword>scarring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Bacitracin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

